Patents by Inventor Eva Kontsekova
Eva Kontsekova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220402979Abstract: The disclosure provides immunogenic peptides, compositions, means, and methods for treating Alzheimer's disease or mild cognitive impairment. The disclosure further provides means and methods for diagnosing patients, selecting patients for treatment, and/or evaluating the efficacy of treatment for Alzheimer's disease or mild cognitive impairment.Type: ApplicationFiled: September 8, 2020Publication date: December 22, 2022Inventors: Michal NOVAK, Eva KONTSEKOVÁ, Branislav KOVACECH, Norbert ZILKA
-
Patent number: 11319363Abstract: The present invention is in the fields of biochemistry, molecular biology, and Alzheimer's disease diagnosis, prevention, and treatment. Provided herein are humanized antibodies against human tau that are capable of discriminating between normal (healthy) and pathological (disease-associated) tau.Type: GrantFiled: July 10, 2020Date of Patent: May 3, 2022Assignee: AXON NEUROSCIENCE SEInventors: Michal Novak, Eva Kontsekova, Branislav Kovacech, Rostislav Skrabana
-
Publication number: 20220010004Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or pep tide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: ApplicationFiled: July 27, 2021Publication date: January 13, 2022Inventors: Michal NOVÁK, Eva KONTSEKOVÁ, Branislav KOVÁCECH, Norbert ZILKA
-
Patent number: 11098106Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: GrantFiled: November 2, 2017Date of Patent: August 24, 2021Assignee: Axon Neuroscience SEInventors: Michal Novák, Eva Kontseková, Branislav Kovácech, Norbert Zilka
-
Publication number: 20210139568Abstract: Disclosed herein are antibodies and antigen binding fragments that bind phosphorylated and dephosphorylated tau and methods of use in detecting and treating Alzheimer's disease and other tauopathies. Also included are methods for determining the stage of Alzheimer's disease in a human subject and monitoring the effectiveness of an anti-tau therapy.Type: ApplicationFiled: March 27, 2019Publication date: May 13, 2021Applicant: Axon NeuroScience SEInventors: Jozef HANES, Eva KONTSEKOVÁ, Andrej KOVÁC, Norbert ZILKA
-
Publication number: 20210009666Abstract: The present invention is in the fields of biochemistry, molecular biology, and Alzheimer's disease diagnosis, prevention, and treatment. Provided herein are humanized antibodies against human tau that are capable of discriminating between normal (healthy) and pathological (disease-associated) tau.Type: ApplicationFiled: July 10, 2020Publication date: January 14, 2021Inventors: Michal NOVAK, Eva KONTSEKOVA, Branislav KOVACECH, Rostislav SKRABANA
-
Patent number: 10745469Abstract: The present invention is in the fields of biochemistry, molecular biology, and Alzheimer's disease diagnosis, prevention, and treatment. Provided herein are humanized antibodies against human tau that are capable of discriminating between normal (healthy) and pathological (disease-associated) tau.Type: GrantFiled: November 5, 2018Date of Patent: August 18, 2020Assignee: Axon Neuroscience SEInventors: Michal Novak, Eva Kontsekova, Branislav Kovacech, Rostislav Skrabana
-
Publication number: 20190169276Abstract: The present invention is in the fields of biochemistry, molecular biology, and Alzheimer's disease diagnosis, prevention, and treatment. Provided herein are humanized antibodies against human tau that are capable of discriminating between normal (healthy) and pathological (disease-associated) tau.Type: ApplicationFiled: November 5, 2018Publication date: June 6, 2019Applicant: AXON NEUROSCIENCE SEInventors: Michal Novak, Eva Kontsekova, Branislav Kovacech, Rostislav Skrabana
-
Patent number: 10160799Abstract: The present invention is in the fields of biochemistry, molecular biology, and Alzheimer's disease diagnosis, prevention, and treatment Provided herein are humanized antibodies against human tau that are capable of discriminating between normal (healthy) and pathological (disease-associated) tau.Type: GrantFiled: November 18, 2015Date of Patent: December 25, 2018Assignee: Axon Neuroscience SEInventors: Michal Novak, Eva Kontsekova, Branislav Kovacech, Rostislav Skrabana
-
Publication number: 20180282401Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: ApplicationFiled: November 2, 1918Publication date: October 4, 2018Inventors: Michal Novák, Eva Kontseková, Branislav Kovácech, Norbert Zilka
-
Publication number: 20180142007Abstract: The present invention is in the fields of biochemistry, molecular biology, and Alzheimer's disease diagnosis, prevention, and treatment Provided herein are humanized antibodies against human tau that are capable of discriminating between normal (healthy) and pathological (disease-associated) tau.Type: ApplicationFiled: November 18, 2015Publication date: May 24, 2018Applicant: AXON NEUROSCIENCE SEInventors: Michal NOVAK, Eva KONTSEKOVA, Branislav KOVACECH, Rostislav SKRABANA
-
Patent number: 9845352Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: GrantFiled: May 19, 2017Date of Patent: December 19, 2017Assignee: AXON NEUROSCIENCE SEInventors: Michal Novák, Eva Kontseková, Branislav Kováce{hacek over (c)}h, Norbert {hacek over (Z)}ilka
-
Patent number: 9828421Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: GrantFiled: November 3, 2016Date of Patent: November 28, 2017Assignee: Axon Neuroscience SEInventors: Michal Novák, Eva Kontseková, Branislav Kováce{hacek over (c)}h, Norbert {hacek over (Z)}ilka
-
Publication number: 20170260263Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: ApplicationFiled: May 19, 2017Publication date: September 14, 2017Inventors: Michal NOVÁK, Eva KONTSEKOVÁ, Branislav KOVÁCECH, Norbert ZILKA
-
Publication number: 20170145082Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: ApplicationFiled: November 3, 2016Publication date: May 25, 2017Inventors: Michal NOVÁK, Eva KONTSEKOVÁ, Branislav KOVÁCECH, Norbert ZILKA
-
Patent number: 9518101Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: GrantFiled: September 14, 2012Date of Patent: December 13, 2016Assignee: AXON NEUROSCIENCE SEInventors: Michal Novak, Eva Kontseková, Branislav Kovácech, Norbert Zilka
-
Patent number: 9485972Abstract: Described are novel N- and C-terminally double truncated tau molecules, (“type IA, IB, IIA and IIB tau molecules”) as well as methods for providing these molecules, both from recombinant and biological sources. Moreover, screening methods using these molecules in connection with Alzheimer's diagnosis and therapy are provided.Type: GrantFiled: October 6, 2009Date of Patent: November 8, 2016Assignee: Axon Neuroscience SEInventor: Eva Kontsekovà
-
Publication number: 20160106077Abstract: The present invention provides transgenic non-human animals and non-human mammalian somatic and germ cells harbouring a human DNA sequence encoding Alzheimer's Disease (AD) derived tau protein, capable of inducing AD pathology in transgenic animals. Alzheimer's tau protein is expressed on specific genetic backgrounds allowing also simulation of different human diseases including hypertension, diabetes, hyper-cholesterolemia, which are associated with neurodegeneration and are considerable risk factors for AD development. Transgenic animals and cells of the present invention exhibit neurofibrillary pathology and may serve as in vivo and also in vitro assay systems for screening and developing therapeutic and preventive substances and also diagnostic markers and probes for tauopathies and AD.Type: ApplicationFiled: September 10, 2015Publication date: April 21, 2016Applicant: AXON NEUROSCIENCE SEInventors: EVA KONTSEKOVÁ, PETER FILIPCIK
-
Patent number: 9161520Abstract: The present invention provides transgenic non-human animals and non-human mammalian somatic and germ cells harboring a human DNA sequence encoding Alzheimer's Disease (AD) derived tau protein, capable of inducing AD pathology in transgenic animals. Alzheimer's tau protein is expressed on specific genetic backgrounds allowing also simulation of different human diseases including hypertension, diabetes, hyper-cholesterolemia, which are associated with neurodegeneration and are considerable risk factors for AD development. Transgenic animals and cells of the invention exhibit neurofibrillary pathology and may serve as in vivo and in vitro assay systems for screening and developing therapeutic and preventive substances and also diagnostic markers and probes for tauopathies and AD.Type: GrantFiled: September 14, 2012Date of Patent: October 20, 2015Assignee: Axon Neuroscience SEInventors: Eva Kontsekovà, Peter Filipcik
-
Publication number: 20150050215Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: ApplicationFiled: September 14, 2012Publication date: February 19, 2015Applicant: Axon Neuroscience SEInventors: Michal Novak, Eva Kontseková, Branislav Kovácech, Norbert Zilka